Medicus Pharma to Highlight Rationale for CD228V Co-Development and License Agreement
The proposed SkinJect structure seeks dedicated financing while Medicus aims to retain majority economic and voting ownership.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Medicus Pharma (NASDAQ:MDCX) outlined plans to prioritize CD228V development and pursue a separate public listing for its SkinJect subsidiary.
The Pfizer co-development and license agreement covers CD228V, an antibody-drug conjugate intended to deliver a drug to targeted cells. Medicus plans to focus on melanoma resistant to immunotherapy. SkinJect's non-binding SPAC proposal contemplates an approximately $135 million pre-money enterprise valuation, with completion anticipated in the first half of 2027. Financing and definitive agreements remain pending; Medicus seeks majority ownership.
Third-quarter 2026 net loss narrowed to $15.2 million from $16.0 million, while nine-month net loss widened to $35.9 million from $27.3 million. Cash and cash equivalents were $5.0 million at September 30, alongside $8.1 million in restricted cash. Management expects operating expenses to decline in coming quarters.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major pointEquity and secured debt financings raised approximately $42.6 million net of issuance costs during the nine-month period. 12× market cap
- Moderate pointThe Pfizer CD228V co-development and license agreement provides worldwide rights for Medicus.
- Moderate point. Forward-looking: it has not happened yet and may not happen.The proposed SkinJect transaction contemplates an approximately $135 million pre-money enterprise valuation.
- Moderate point. Forward-looking: it has not happened yet and may not happen.SkinJect's proposed separate listing seeks dedicated financing, with Medicus seeking majority economic and voting ownership.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Concurrent equity financing is contemplated for SKNJCT-005 and preparation and submission of a potential New Drug Application.
- Moderate pointDebt repayments totaled approximately $6.4 million during the nine-month period. 1.8× market cap
- Moderate point. Forward-looking: it has not happened yet and may not happen.Management anticipates a substantial reduction in operating expenses in coming quarters.
4 minor points
- Minor point. Forward-looking: it has not happened yet and may not happen.Medicus plans to prioritize CD228V development in melanoma resistant to immunotherapy.
- Minor pointThird-quarter operating expenses fell to $14.5 million from $15.4 million in 2025.
- Minor pointThird-quarter net loss narrowed to $15.2 million from $16.0 million in 2025.
- Minor pointMedicus is seeking Teverelix partners while maintaining the program's readiness.
Negative
- Major pointNine-month net loss widened to $35.9 million from $27.3 million in 2025.
- Moderate pointNine-month operating expenses rose to $34.5 million from $26.6 million in 2025.
- Moderate pointCash and cash equivalents declined to $5.0 million from $8.7 million at December 31, 2025.
- Moderate pointSkinJect's non-binding LOI still requires definitive agreements and financing; majority ownership retention is uncertain.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Anticipated SkinJect completion in the first half of 2027 remains uncertain.
- Moderate point. Forward-looking: it has not happened yet and may not happen.SkinJect program costs are projected at approximately $3 million over the next two years, subject to execution and regulatory requirements.
3 minor points
- Minor point. Forward-looking: it has not happened yet and may not happen.CD228V's company-envisioned melanoma response rate exceeding 30% remains to be demonstrated in clinical trials.
- Minor point. Forward-looking: it has not happened yet and may not happen.A future CD228V monotherapy registration strategy depends on durable responses, acceptable safety and applicable regulatory requirements.
- Minor pointTeverelix's optimized prostate cancer protocol remains subject to FDA feedback.
News Explained
Medicus says CD228V could produce an objective response rate above
Key Figures
- Proposed pre-money enterprise valuation
- Approximately $135 million
- SkinJect SPAC transaction under a non-binding LOI
- Projected SkinJect program cost
- Approximately $3 million
- Next two years; subject to execution and regulatory requirements
- Financing raised
- Approximately $42.6 million
- Nine months ended September 30, 2026; equity and secured debt, net of issuance costs
- Net cash from financing activities
- $36.2 million
- Nine months ended September 30, 2026, after approximately $6.4 million in debt repayments
- Operating expenses
- $14.5 million
- Q3 2026 vs. $15.4 million in Q3 2025
- Net loss
- $15.2 million
- Q3 2026 vs. $16.0 million in Q3 2025
- Net loss
- $35.9 million
- Nine months ended September 30, 2026 vs. $27.3 million in the prior-year period
- Cash and restricted cash
- $13.1 million
- As of September 30, 2026; includes $5.0 million cash and cash equivalents and $8.1 million restricted cash
Historical Context
-
Non-binding LOI proposed a $135 million pre-money valuation and share consideration for 100% of SkinJect.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
antibody-drug conjugate medical
open-label medical
objective response rate medical
pre-money enterprise valuation financial
new drug application regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
PHILADELPHIA, PA / ACCESS Newswire / November 9, 2026 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided, biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today outlined key highlights for its third quarter 2026 financial performance and business update conference call at 11:30 a.m. Eastern Time today, following the filing of its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026.
Management will explain the scientific and clinical rationale for the Company's CD228V agreement with Pfizer Inc. ("Pfizer"), the proposed transaction between its wholly owned subsidiary, SkinJect, Inc. ("SkinJect"), and an undisclosed special purpose acquisition company ("SPAC") (the "Transaction" or the "Business Combination") and the Company's approach to capital efficiency.
Medicus' strategy is to concentrate incremental development investment on CD228V, pursue a separate public listing and dedicated financing for SkinJect® and preserve Teverelix®'s readiness for partnering. The Company believes this approach can advance its precision oncology focus while preserving Medicus shareholders' participation in the potential value of its broader portfolio.
Conference Call Details
Date and time: Monday, November 9, 2026, at 11:30 a.m. ET
Dial-in (U.S./Canada, toll-free): 1-833-890-6070
Dial-in (international): 1-412-504-9736
Webcast: Access the live webcast
Participants will include Raza Bokhari, MD, Executive Chairman and Chief Executive Officer; Carolyn Bonner, President and Chief Financial Officer; and Faisal Mehmud, MD, Chief Medical Officer.
CD228V Agreement Rationale, Melanoma Focus and ADC Opportunity
Dr. Raza Bokhari, Executive Chairman and CEO, is expected to describe how Medicus' review of the clinical evidence for the predecessor molecule, SGN-CD228A, Pfizer's refinement of the ADC construct and a focused initial development strategy informed the Company's decision to enter the CD228V co-development and license agreement.
Clinical foundation. The decision was informed by Medicus' review of clinical data from Seagen's open-label Phase 1 study of SGN-CD228A, which enrolled 88 patients with advanced solid tumors, including melanoma and non-small cell lung cancer. This data provided preliminary clinical observations and insights into the CD228 target, safety and biomarkers. Detailed findings from that study have not yet been publicly disclosed.
Construct rationale. CD228V (PF-08046031) is a second-generation, clinical-stage antibody-drug conjugate directed against CD228, also known as melanotransferrin. The molecule uses Pfizer's established vedotin linker-payload platform, with changes to the linker and the amount of payload carried by each antibody. Medicus understands that these refinements were designed to improve the balance between drug exposure, tolerability and anti-tumor activity. Vedotin technology has clinical and regulatory precedent in FDA-approved ADC therapies.
Focused melanoma strategy. Medicus intends to prioritize melanoma that has relapsed, become refractory or resisted immunotherapy. Based on its assessment of the predecessor clinical evidence from SGN-CD228A and the potential benefit of Pfizer's linker-payload reconstruction, the Company believes CD228V has the potential to achieve an objective response rate exceeding
The ADC opportunity. Medicus is emerging as part of approximately 30 clinical-stage ADC developers across the globe. At one end of this field are established companies with approved products and extensive development capabilities; at the other are companies with programs still in clinical research and development. The CD228V agreement also places Medicus amongst a handful of companies advancing Seagen-linked ADC assets through Pfizer collaborations. The rights, economics and clinical maturity of those relationships differ.
The Company believes that worldwide rights, a defined initial clinical objective and evidence generated through development could support future licensing, co-development and other strategic opportunities.
Rationale for the Proposed SkinJect SPAC Transaction
The proposed SkinJect® Transaction is intended to establish a separately listed company with its own access to public capital markets and dedicated financing for Gorlin syndrome development, while Medicus seeks to retain majority economic and voting ownership of the combined company. The Company believes this structure could support SkinJect®'s advancement while allowing Medicus to concentrate incremental investment on precision oncology.
The non-binding letter of intent ("LOI") with the SPAC contemplates an approximately
The Company currently projects approximately
The Company currently anticipates completing the proposed Transaction during the first half of 2027. The LOI is non-binding, and there can be no assurance that definitive agreements will be signed, financing will be secured, Medicus will retain majority ownership, or the Transaction will close within that timeframe or at all.
Capital Efficiency and Portfolio Execution
Medicus intends to align organizational costs and development spending with its portfolio priorities. Incremental capital will be directed toward CD228V, with essential resources allocated to maintain Teverelix®'s value and partnering readiness and pursue the proposed SkinJect®Transaction. Management anticipates a substantial reduction in operating expenses in the coming quarters.
For Teverelix®, Medicus is seeking partners with the capabilities and resources to advance opportunities in urology, advanced prostate cancer and women's health. The optimized prostate cancer protocol remains subject to FDA feedback. Maintaining program readiness while pursuing partnerships is intended to preserve the asset's potential value within the Company's capital allocation strategy.
Financial Performance Supporting the Strategic Update
Ms. Carolyn Bonner, President and CFO, is expected to describe the Company's financial results for the third quarter and nine months ended September 30, 2026. During the nine-month period, Medicus raised approximately
Selected financial results in U.S. dollars in millions for periods ended September 30
| Metric | Q3 2026 | Q3 2025 | Nine months 2026 | Nine months 2025 |
|---|---|---|---|---|
| Operating expenses | 14.5 | 15.4 | 34.5 | 26.6 |
| Net loss | (15.2) | (16.0) | (35.9) | (27.3) |
Nine-month operating expenses included
On September 30, 2026, Medicus held
For further information contact:
Carolyn Bonner, President and Chief Financial Officer
(610) 636-0184
cbonner@medicuspharma.com
Anna Baran-Djokovic, SVP Investor Relations
(305) 615-9162
adjokovic@medicuspharma.com
About Medicus Pharma Ltd.
Medicus Pharma Ltd. (Nasdaq:MDCX) is a precision-guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets. The Company is actively engaged in multiple countries across three continents.
The Company's current therapeutic assets are:
CD228V ADC, an investigational antibody-drug conjugate molecule utilizing Pfizer's established vedotin linker-payload platform, directed against melanotransferrin (CD228), a cell-surface protein expressed across multiple solid tumor types, such as melanoma, squamous non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), and esophageal cancer.
SkinJect®, an investigational novel localized immuno-oncology precision product focused on basal cell carcinoma (BCC) lesions in Gorlin Syndrome patients, a rare autosomal dominant disease also called nevoid BCC syndrome.
Teverelix®, an investigational next-generation GnRH antagonist, is being developed as a first-in-market product for cardiovascular high-risk advanced prostate cancer patients, patients with acute urinary retention relapse (AURr) episodes due to enlarged prostate and symptomatic endometriosis.
Medicus' strategy is to advance select programs through Phase 2 proof-of-concept and key clinical and regulatory inflection points that substantially reduce development risk and increase their attractiveness to potential pharmaceutical partners. By generating decision-grade clinical, regulatory and operational datasets, the Company seeks to create opportunities for strategic collaborations, regional licensing transactions and broader commercialization partnerships with established pharmaceutical companies. As data matures across its programs, Medicus intends to continue building differentiated development packages designed to maximize asset value while maintaining capital efficiency and development focus.
Important Information and Where to Find It
This press release is provided for informational purposes only and contains information with respect to a potential Business Combination described herein. If the parties enter into definitive documentation regarding the Business Combination, it is anticipated that SPAC and/or Medicus will file relevant materials with the Securities and Exchange Commission (the "SEC"), including, as may be applicable, a registration statement on Form S-4, that includes a preliminary proxy statement/prospectus, and when available, a definitive proxy statement and final prospectus. Promptly after filing any Medicus definitive proxy statement with the SEC, Medicus will mail the definitive proxy statement and a proxy card to each shareholder entitled to vote at any applicable special shareholder meeting relating to the Business Combination. INVESTORS AND SHAREHOLDERS ARE URGED TO READ THESE MATERIALS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS IN CONNECTION WITH THE TRANSACTION THAT SPAC OR MEDICUS FILE WITH THE SEC IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT SPAC, MEDICUS, SKINJECT AND THE BUSINESS COMBINATION. Any definitive proxy statement, preliminary proxy statement and other relevant materials in connection with the transaction (if and when they become available), and any other documents filed by SPAC or Medicus with the SEC, may be obtained free of charge at the SEC's website (www.sec.gov).
Participants in the Solicitation
Medicus, SkinJect and their respective directors and executive officers may be deemed participants in the solicitation of proxies from Medicus' shareholders with respect to the Business Combination. A list of the names of those directors and executive officers and a description of their interests in Medicus and SkinJect will be included in any proxy statement for the Business Combination and be available at www.sec.gov. Information about Medicus' directors and executive officers and their ownership of Medicus' common shares is set forth in Medicus' proxy statement for its 2026 annual general and special meeting of shareholders, filed with the SEC (File No. 001-42408) on May 4, 2026. Additional information regarding the interests of the participants in the proxy solicitation will be included in the proxy statement pertaining to the proposed Business Combination when it becomes available. These documents can be obtained free of charge at the SEC's website (www.sec.gov).
The SPAC and its directors and executive officers may also be deemed to be participants in the solicitation of proxies from the shareholders of Medicus in connection with the proposed Business Combination. A list of the names of such directors and executive officers and information regarding their interests in the proposed Business Combination will be included in any proxy statement for the proposed Business Combination when it becomes available.
No Offer or Solicitation
This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, or a recommendation to purchase, any securities in any jurisdiction, or the solicitation of any vote, consent or approval in any jurisdiction in respect of the proposed Business Combination, nor shall there be any sale, issuance or transfer of any securities in any jurisdiction where, or to any person to whom, such offer, solicitation or sale may be unlawful under the laws of such jurisdiction. This press release does not constitute either advice or a recommendation regarding any securities. No offering of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended, or an exemption therefrom.
Cautionary Notice on Forward-Looking Statements
Certain information in this news release constitutes "forward-looking statements" or "forward-looking information" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other applicable securities laws (collectively, "forward-looking statements"). "Forward-looking statements" are defined as disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action and includes, without limitation, statements regarding the Company's financial performance and business outlook, the proposed Business Combination contemplated by the non-binding LOI, including the anticipated terms, structure and timing thereof, the anticipated capitalization and ownership of the combined company, including Medicus' intention to retain majority economic and voting ownership of the combined company, the satisfaction of closing conditions, the anticipated completion of the proposed Business Combination during the first half of 2027 or at all, the anticipated benefits of the proposed Business Combination to Medicus and its shareholders, the proposed concurrent equity financing, including the amount, terms and anticipated use of proceeds thereof, the ability of the parties to complete due diligence and to negotiate and execute definitive agreements, the development of SkinJect® and the potential benefits thereof for those suffering with Gorlin Syndrome, the planned initiation, timing, design, conduct and results of the SKNJCT-005 registrational study in patients with Gorlin Syndrome, the projected cost of the SkinJect® development program, the Company's decision to develop SkinJect® exclusively for patients with Gorlin Syndrome, the timing and outcome of the FDA's review of the Company's Orphan Drug Designation and Rare Pediatric Disease Designation applications for SkinJect®, the development of Teverelix® and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of Teverelix® for AURr, cardiovascular high-risk advanced prostate cancer ("APC"), women's health indications like endometriosis, the FDA's feedback regarding the Company's Phase 2b/3 registration-intent protocol for Teverelix® in APC, the proposed design of the Phase 2b/3 registration-intent program, the potential to reduce the overall planned APC clinical development program from approximately 1,500 patients to approximately 600 patients, the establishment of a defined, capital-efficient and partner-ready registrational pathway for Teverelix® without Medicus independently funding an additional APC clinical development study, Medicus' intent and ability to out-license or otherwise strategically partner the Teverelix® APC program, the anticipated completion of GMP-grade manufacturing, quality-release and other clinical study readiness steps, whether the proposed cardiovascular-focused registrational strategy, including the 12-month non-calcified coronary plaque endpoint assessed using non-invasive coronary CCTA and the evaluation of Teverelix® effects on APC patients at increased cardiovascular risk, could support registration, the Company's capital-efficient portfolio strategy and the anticipated benefits thereof, the anticipated reduction in the Company's operating expenses, the Company's view that SkinJect® and Teverelix® are partner-ready programs, the Company's co-development and license agreement with Pfizer with respect to CD228V, the Company's strategy relating thereto and the anticipated benefits thereof, including whether Pfizer elects to fund any development activities for CD228V and whether the parties enter into a definitive agreement in respect thereof, the Company's ability to identify, negotiate and complete partnerships, licensing, co-development or other strategic transactions and the timing, terms and anticipated benefits thereof, the Company's plans and expectations relating to the development, manufacture and commercialization of CD228V across human therapeutic indications, including the Company's intention to focus initial development on melanoma with potential subsequent development in squamous non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC) and esophageal cancer, the Company's plans to prioritize clinical proof-of-concept for CD228V in melanoma, including relapsed, refractory or immunotherapy-resistant disease, the potential for CD228V to achieve an objective response rate exceeding
SOURCE: Medicus Pharma Ltd
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What are the proposed terms of Medicus Pharma's SkinJect SPAC transaction?
The non-binding proposal contemplates an approximately $135 million pre-money enterprise valuation for SkinJect. The SPAC would acquire 100% of SkinJect in exchange for newly issued common shares of the combined company. Medicus seeks to retain majority economic and voting ownership and anticipates completion during the first half of 2027, but definitive agreements and financing remain pending.
What evidence supports Medicus Pharma's CD228V melanoma development plan?
Medicus based its decision partly on its review of a predecessor molecule's open-label Phase 1 study involving 88 patients with advanced solid tumors, including melanoma and non-small cell lung cancer. The SGN-CD228A study provided preliminary observations on the target, safety and biomarkers; detailed findings have not yet been publicly disclosed.
What changes distinguish Medicus Pharma's CD228V from its predecessor?
CD228V uses Pfizer's vedotin linker-payload platform with changes to the linker and the amount of drug carried by each antibody. Medicus understands that these refinements were designed to improve the balance between drug exposure, tolerability and anti-tumor activity.